Lucknow, Aug 13 (Ians) The Csir-Central Drug Research Institute (Cdri) in Lucknow has introduced an innovative contraceptive named ‘Levormeloxifene’.
The breakthrough contraceptive is notably more effective to the human body with its reduced dose and chemical burden compared to existing market options.
Levormeloxifene is a modernised version of the 1990s ‘Saheli’ pill, initially developed by Cdri. Once a staple during the 1990s, Saheli, also known as ‘Chaya’ under the National Family Planning programme, has now evolved into Levormeloxifene.
Radha Rangarajan, Director of Csir-cdri, explained, “The core objective behind this contraceptive’s development was to minimise the chemical content, particularly crucial for women in their reproductive phase who predominantly consume such tablets.”
Rangarajan elaborated, “The compound ormeloxifene within Saheli comprises two enantiomers, dextro-ormeloxifene, and levo-ormeloxifene (levormeloxifene). Extensive preclinical studies have indicated higher efficacy of the levo counterpart, levormeloxifene. This research solely focuses on testing the levo model as a contraceptive, thereby reducing...
The breakthrough contraceptive is notably more effective to the human body with its reduced dose and chemical burden compared to existing market options.
Levormeloxifene is a modernised version of the 1990s ‘Saheli’ pill, initially developed by Cdri. Once a staple during the 1990s, Saheli, also known as ‘Chaya’ under the National Family Planning programme, has now evolved into Levormeloxifene.
Radha Rangarajan, Director of Csir-cdri, explained, “The core objective behind this contraceptive’s development was to minimise the chemical content, particularly crucial for women in their reproductive phase who predominantly consume such tablets.”
Rangarajan elaborated, “The compound ormeloxifene within Saheli comprises two enantiomers, dextro-ormeloxifene, and levo-ormeloxifene (levormeloxifene). Extensive preclinical studies have indicated higher efficacy of the levo counterpart, levormeloxifene. This research solely focuses on testing the levo model as a contraceptive, thereby reducing...
- 8/13/2023
- by Agency News Desk
- GlamSham
Mumbai, Jan 3 (Ians) Amanullah Shaikh of Andhra Pradesh showed steely nerves as he recorded to score a nail-biting 4-3 victory against home challenger Ajinkya Yelve in a second-round match of the Rs 13 lakh prize-money Nsci All India Snooker Open 2023, here on Tuesday.
In a tournament that has the likes of Asian Games medallist Rafat Habib and Devendra Joshi, Shaikh took the spotlight on Tuesday as he hit form at the opportune moment to win 58-45, 9-85, 72-38, 62-49, 9-61, 29-58, 62-58 against Yelve at the Nsci billiards hall in the afternoon.
Later, in the evening, Nikhil Saigal, after a hesitant start, came into his own and pulled off a 4-2 win against Sukeel Venkatramani in a second round qualifying match.
Both Shaikh and Saigal have now qualified among the 32- players for the main draw and will be joined by 32 leading Indian players who have received direct entries to the final round of the tournament.
In a tournament that has the likes of Asian Games medallist Rafat Habib and Devendra Joshi, Shaikh took the spotlight on Tuesday as he hit form at the opportune moment to win 58-45, 9-85, 72-38, 62-49, 9-61, 29-58, 62-58 against Yelve at the Nsci billiards hall in the afternoon.
Later, in the evening, Nikhil Saigal, after a hesitant start, came into his own and pulled off a 4-2 win against Sukeel Venkatramani in a second round qualifying match.
Both Shaikh and Saigal have now qualified among the 32- players for the main draw and will be joined by 32 leading Indian players who have received direct entries to the final round of the tournament.
- 1/3/2023
- by News Bureau
- GlamSham
IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news articles, Tweets, and blog posts do not represent IMDb's opinions nor can we guarantee that the reporting therein is completely factual. Please visit the source responsible for the item in question to report any concerns you may have regarding content or accuracy.